<?xml version="1.0" encoding="UTF-8"?><protocol_summary><protocol><id>13845</id><no>STEP-1</no><status>Open</status><title>A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study </title><objective>A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study.&#xD;
&#xD;
A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the EndoBarrier System plus moderate intensity lifestyle and dietary counseling compliant with 2019 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (EndoBarrier):1 (Sham).</objective><secondary_protocol_no>20183128</secondary_protocol_no><nct_id>NCT04101669</nct_id><sponsor_type>Industrial</sponsor_type><age_group>Adult</age_group><treatment_type>Treatment</treatment_type><treatment>Device: EndoBarrier Liner&#xD;
Other: Sham</treatment><phase>N/A</phase><disease_site>Other</disease_site><lay_description>Diabetes type2&#xD;
Obesity</lay_description><PI>Brebbia, John</PI><institution>Medstar Montgomery Medical Center; Medstar Washington Hospital Center</institution><management_group>MedStar Medical &amp; Surgical Research Network</management_group></protocol><sipVersion>2026.1.0 Build 16</sipVersion><copyright> &lt;a href="https://advarra.com" target="_blank"&gt;&amp;copy; 2026 Advarra, Inc.&lt;/a&gt; </copyright></protocol_summary>